Methylglyoxal-Derived Advanced Glycation Endproducts in Multiple Sclerosis.
about
Oxidative Modification of Blood Serum Proteins in Multiple Sclerosis after Interferon Beta and Melatonin Treatment.Probing Protein Glycation by Chromatography and Mass Spectrometry: Analysis of Glycation Adducts.Curcumin against advanced glycation end products (AGEs) and AGEs-induced detrimental agents.Methylglyoxal Disrupts Paranodal Axoglial Junctions via Calpain Activation.Advanced Glycation Endproducts Are Increased in the Animal Model of Multiple Sclerosis but Cannot Be Reduced by Pyridoxamine Treatment or Glyoxalase 1 Overexpression.Glycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging
P2860
Methylglyoxal-Derived Advanced Glycation Endproducts in Multiple Sclerosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Methylglyoxal-Derived Advanced Glycation Endproducts in Multiple Sclerosis.
@en
Methylglyoxal-Derived Advanced Glycation Endproducts in Multiple Sclerosis.
@nl
type
label
Methylglyoxal-Derived Advanced Glycation Endproducts in Multiple Sclerosis.
@en
Methylglyoxal-Derived Advanced Glycation Endproducts in Multiple Sclerosis.
@nl
prefLabel
Methylglyoxal-Derived Advanced Glycation Endproducts in Multiple Sclerosis.
@en
Methylglyoxal-Derived Advanced Glycation Endproducts in Multiple Sclerosis.
@nl
P2860
P50
P921
P356
P1476
Methylglyoxal-Derived Advanced Glycation Endproducts in Multiple Sclerosis
@en
P2093
Casper G Schalkwijk
Suzan Wetzels
P2860
P356
10.3390/IJMS18020421
P407
P5008
P577
2017-02-15T00:00:00Z